• Dimitri A Raptis, Patricia Sánchez-Velázquez, Nikolaos Machairas, Alain Sauvanet, Alexandra Rueda de Leon, Atsushi Oba, Bas Groot Koerkamp, Brendan Lovasik, Carlos Chan, Charles J Yeo, Claudio Bassi, Cristina R Ferrone, David Kooby, David Moskal, Domenico Tamburrino, Dong-Sup Yoon, Eduardo Barroso, Eduardo de Santibañes, Emanuele F Kauffmann, Emanuel Vigia, Fabien Robin, Fabio Casciani, Fernando Burdío, Giulio Belfiori, Giuseppe Malleo, Harish Lavu, Hermien Hartog, Ho Kyuong Hwang, Ho-Seong Han, Ignasi Poves, Ismael Domínguez Rosado, Joon-Seong Park, Keith D Lillemoe, Keith J Roberts, Laurent Sulpice, Marc G Besselink, Mahmoud Abuawwad, Marco Del Chiaro, Martin de Santibañes, Massimo Falconi, Mizelle D'Silva, Michael Silva, Mohammed Abu Hilal, Motaz Qadan, Naomi M Sell, Nassiba Beghdadi, Niccolò Napoli, Busch Olivier R C ORC Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Oscar Mazza, Paolo Muiesan, Philip C Müller, Reena Ravikumar, Richard Schulick, Sarah Powell-Brett, Syed Hussain Abbas, Tara M Mackay, Thomas F Stoop, Tom K Gallagher, Ugo Boggi, Casper van Eijck, Pierre-Alain Clavien, Kevin C P Conlon, and Giuseppe Kito Fusai.
• Department of HPB Surgery and Liver Transplant, Royal Free Hospital NHS Foundation Trust, London, UK.
• Ann. Surg. 2020 Nov 1; 272 (5): 731-737.

ObjectiveThe aim of this study was to establish clinically relevant outcome benchmark values using criteria for pancreatoduodenectomy (PD) with portomesenteric venous resection (PVR) from a low-risk cohort managed in high-volume centers.Summary Background DataPD with PVR is regarded as the standard of care in patients with cancer involvement of the portomesenteric venous axis. There are, however, no benchmark outcome indicators for this population which hampers comparisons of patients undergoing PD with and without PVR resection.MethodsThis multicenter study analyzed patients undergoing PD with any type of PVR in 23 high-volume centers from 2009 to 2018. Nineteen outcome benchmarks were established in low-risk patients, defined as the 75th percentile of the median outcome values of the centers (NCT04053998).ResultsOut of 1462 patients with PD and PVR, 840 (58%) formed the benchmark cohort, with a mean age was 64 (SD11) years, 413 (49%) were females. Benchmark cutoffs, among others, were calculated as follows: Clinically relevant pancreatic fistula rate (International Study Group of Pancreatic Surgery): ≤14%; in-hospital mortality rate: ≤4%; major complication rate Grade≥3 and the CCI up to 6 months postoperatively: ≤36% and ≤26, respectively; portal vein thrombosis rate: ≤14% and 5-year survival for patients with pancreatic ductal adenocarcinoma: ≥9%.ConclusionThese novel benchmark cutoffs targeting surgical performance, morbidity, mortality, and oncological parameters show relatively inferior results in patients undergoing vascular resection because of involvement of the portomesenteric venous axis. These benchmark values however can be used to conclusively assess the results of different centers or surgeons operating on this high-risk group.

16 keywords...

hide…